FERMENTALG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.566 EUR | +0.89% |
|
-5.98% | +87.42% |
| Apr. 12 | Fermentalg: transfer to Euronext Growth on April 16 | CF |
| Apr. 04 | Fermentalg SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2023 | 4.06M 4.35M | Sales 2024 * | 9.8M 10.51M | Capitalization | 23.32M 25.01M |
|---|---|---|---|---|---|
| Net income 2023 | -14M -15.02M | Net income 2024 * | -10M -10.73M | EV / Sales 2023 | 3.07 x |
| Net Debt 2023 * | 2.4M 2.57M | Net Debt 2024 * | 13.3M 14.27M | EV / Sales 2024 * | 3.74 x |
| P/E ratio 2023 |
-0.94
x | P/E ratio 2024 * |
-2.57
x | Employees | 57 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.12% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.89% | ||
| 1 week | -5.98% | ||
| Current month | -17.73% | ||
| 1 month | -7.21% | ||
| 3 months | +50.53% | ||
| 6 months | +142.40% | ||
| Current year | +87.42% |
1 week
0.54
0.60
1 month
0.530.75
Current year
0.270.99
1 year
0.211.04
3 years
0.213.50
5 years
0.214.85
10 years
0.219.18
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Josselin
CEO | Chief Executive Officer | - | 23-05-03 |
| Director of Finance/CFO | - | - | |
| Chairman | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gilles Schang
BRD | Director/Board Member | - | - |
| Chairman | - | - | |
| Director/Board Member | 56 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.566 | +0.89% | 132,123 |
| 24-04-24 | 0.561 | -2.60% | 87,960 |
| 24-04-23 | 0.576 | -2.70% | 91,857 |
| 24-04-22 | 0.592 | -1.00% | 98,100 |
| 24-04-19 | 0.598 | -0.66% | 115,909 |
Real-time Euronext Paris, April 25, 2024 at 11:35 am EDT
More quotes
Fermentalg is an expert in the research and bio-industrial exploitation of micro-algae and aims to provide sustainable solutions and innovative products that contribute to the development of healthy, natural and high-performance products. Its business: the development, production and marketing of sustainable solutions and active ingredients derived from microalgae for nutrition, health and the environment. Nutritional lipids, alternative proteins and natural food colorants make up the company's current and future offer.
Calendar
2024-07-13
- Q2 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.566
EUR
Average target price
0.5
EUR
Spread / Average Target
-11.66%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +87.42% | 24.7M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- ALGAE Stock
